Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Langan SM, Smeeth L, Margolis DJ, Thomas SL.

PLoS Med. 2013;10(4):e1001420. doi: 10.1371/journal.pmed.1001420. Epub 2013 Apr 9.

2.

Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.

Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, Luo Y, Jacobsen SJ, Reddy K, Huang PY, Zhang J, Anand S, Bauer EM, Chang J, Tartof SY.

J Infect Dis. 2015 Oct 15;212(8):1222-31. doi: 10.1093/infdis/jiv244. Epub 2015 Jun 1.

3.

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Pellissier JM, Brisson M, Levin MJ.

Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.

PMID:
17980938
4.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45. Epub 2010 May 25.

PMID:
18382137
5.

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.

BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.

6.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
7.

Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.

Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R.

Hum Vaccin Immunother. 2015;11(5):1157-64. doi: 10.1080/21645515.2015.1016681.

8.

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.

Annemans L, Bresse X, Gobbo C, Papageorgiou M.

J Med Econ. 2010;13(3):537-51. doi: 10.3111/13696998.2010.502854.

PMID:
20707768
9.

Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.

Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ.

J Manag Care Spec Pharm. 2016 Jul;22(7):872-88. doi: 10.18553/jmcp.2016.22.7.872.

10.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.

PMID:
17443464
11.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Hornberger J, Robertus K.

Ann Intern Med. 2006 Sep 5;145(5):317-25.

PMID:
16954357
12.

Vaccination against herpes zoster in developed countries: state of the evidence.

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.

Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Review.

13.

Cost effectiveness of herpes zoster vaccine in Canada.

Najafzadeh M, Marra CA, Galanis E, Patrick DM.

Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

PMID:
19908924
14.

Vaccination against zoster remains effective in older adults who later undergo chemotherapy.

Tseng HF, Tartof S, Harpaz R, Luo Y, Sy LS, Hetcher RC, Jacobsen SJ.

Clin Infect Dis. 2014 Oct;59(7):913-9. doi: 10.1093/cid/ciu498. Epub 2014 Aug 4.

PMID:
25097079
15.

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR.

JAMA. 2012 Jul 4;308(1):43-9. doi: 10.1001/jama.2012.7304.

16.

Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.

Johnson RW.

Aging Clin Exp Res. 2009 Jun;21(3):236-43. Review.

PMID:
19571648
17.

Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.

Betts RF.

J Am Acad Dermatol. 2007 Dec;57(6 Suppl):S143-7.

PMID:
18021866
18.

Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.

Le P, Rothberg MB.

Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.

PMID:
26344036
19.

Vaccination against Herpes Zoster and Postherpetic Neuralgia.

Oxman MN, Levin MJ; Shingles Prevention Study Group..

J Infect Dis. 2008 Mar 1;197 Suppl 2:S228-36. doi: 10.1086/522159.

20.

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

Hum Vaccin. 2011 Jul;7(7):749-56. doi: 10.4161/hv.7.7.15573. Epub 2011 Jul 1.

Supplemental Content

Support Center